Literature DB >> 18171294

Immune reconstitution of CD56(dim) NK cells in individuals with primary HIV-1 infection treated with interleukin-2.

Jakob Michaëlsson1, Brian R Long, Christopher P Loo, Lewis L Lanier, Gerald Spotts, Frederick M Hecht, Douglas F Nixon.   

Abstract

Natural killer (NK) cells are believed to play a role in human immunodeficiency virus type 1 (HIV-1) disease progression, and NK cell levels are reduced in individuals with chronic HIV-1 infection. Interleukin (IL)-2 therapy results in an expansion of CD4(+) T cells as well as NK cells; however, little is known about the detailed effects of IL-2 therapy on NK cells in HIV-1 infection in general and in early infection in particular. Here, we investigated the effects of combined IL-2 therapy and antiretroviral therapy (ART) on the number, frequency, phenotype, and interferon (IFN)-gamma production of NK cells in individuals with early HIV-1 infection. Patients randomized to receive combined ART and IL-2 therapy predominantly expanded CD56(dim) NK cells, and the expansion was greater than in patients randomized to receive ART alone. Importantly, NK cell receptor expression and IFN-gamma production were maintained over time. This reconstitution of NK cells may be useful in helping contain viremia if patients discontinue therapy or develop drug resistance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18171294      PMCID: PMC4061976          DOI: 10.1086/524141

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  46 in total

1.  Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection.

Authors:  Mark Dybul; Bertha Hidalgo; Tae-Wook Chun; Michael Belson; Stephen A Migueles; Jesse S Justement; Betsey Herpin; Cheryl Perry; Claire W Hallahan; Richard T Davey; Julia A Metcalf; Mark Connors; Anthony S Fauci
Journal:  J Infect Dis       Date:  2001-12-14       Impact factor: 5.226

2.  Subcutaneous interleukin-2 in combination with anti-retroviral therapy for treatment of HIV-1-infected subjects.

Authors:  C S Larsen; L Ostergård; B K Møller; M R Buhl
Journal:  Scand J Infect Dis       Date:  2000

Review 3.  The biology of human natural killer-cell subsets.

Authors:  M A Cooper; T A Fehniger; M A Caligiuri
Journal:  Trends Immunol       Date:  2001-11       Impact factor: 16.687

Review 4.  The potential role of interleukin-2 in HIV.

Authors:  R T Mitsuyasu
Journal:  AIDS       Date:  2001-02       Impact factor: 4.177

5.  Effects of subcutaneous interleukin-2 therapy on phenotype and function of peripheral blood mononuclear cells in human immunodeficiency virus infected patients.

Authors:  H Aladdin; C S Larsen; B K Møller; H Ullum; M R Buhl; J Gerstoft; P Skinhøj; B K Pedersen
Journal:  Scand J Immunol       Date:  2000-02       Impact factor: 3.487

6.  Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.

Authors:  V P Khatri; T A Fehniger; R A Baiocchi; F Yu; M H Shah; D S Schiller; M Gould; R T Gazzinelli; Z P Bernstein; M A Caligiuri
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

7.  Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection.

Authors:  T A Fehniger; G Herbein; H Yu; M I Para; Z P Bernstein; W A O'Brien; M A Caligiuri
Journal:  J Immunol       Date:  1998-12-01       Impact factor: 5.422

8.  Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity.

Authors:  N J Meropol; M Porter; L E Blumenson; M J Lindemann; R P Perez; L Vaickus; G M Loewen; P J Creaven; K A Wilkes; M A Giedlin; M A Caligiuri
Journal:  Clin Cancer Res       Date:  1996-04       Impact factor: 12.531

9.  Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.

Authors:  N J Meropol; G M Barresi; T A Fehniger; J Hitt; M Franklin; M A Caligiuri
Journal:  Cancer Immunol Immunother       Date:  1998-08       Impact factor: 6.968

10.  KIR/HLA pleiotropism: protection against both HIV and opportunistic infections.

Authors:  Ying Qi; Maureen P Martin; Xiaojiang Gao; Lisa Jacobson; James J Goedert; Susan Buchbinder; Gregory D Kirk; Stephen J O'Brien; John Trowsdale; Mary Carrington
Journal:  PLoS Pathog       Date:  2006-08       Impact factor: 6.823

View more
  15 in total

Review 1.  Natural killer cells in immunodefense against infective agents.

Authors:  Nicolas Zucchini; Karine Crozat; Thomas Baranek; Scott H Robbins; Marcus Altfeld; Marc Dalod
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

2.  NK cells and CD1d-restricted NKT cells respond in different ways with divergent kinetics to IL-2 treatment in primary HIV-1 infection.

Authors:  C Kuylenstierna; J E Snyder-Cappione; C P Loo; B R Long; V D Gonzalez; J Michaëlsson; M Moll; G Spotts; F M Hecht; D F Nixon; J K Sandberg
Journal:  Scand J Immunol       Date:  2011-02       Impact factor: 3.487

Review 3.  Natural killer cells in HIV-1 infection and therapy.

Authors:  Joanna Mikulak; Ferdinando Oriolo; Elisa Zaghi; Clara Di Vito; Domenico Mavilio
Journal:  AIDS       Date:  2017-11-13       Impact factor: 4.177

4.  IL-21 augments natural killer effector functions in chronically HIV-infected individuals.

Authors:  Natasa Strbo; Lesley de Armas; Huanliang Liu; Michael A Kolber; Mathias Lichtenheld; Savita Pahwa
Journal:  AIDS       Date:  2008-08-20       Impact factor: 4.177

5.  Perturbation of the natural killer cell compartment during primary human immunodeficiency virus 1 infection primarily involving the CD56 bright subset.

Authors:  Paola Mantegani; Giuseppe Tambussi; Laura Galli; Chiara Tassan Din; Adriano Lazzarin; Claudio Fortis
Journal:  Immunology       Date:  2009-08-04       Impact factor: 7.397

6.  Increased number and function of natural killer cells in human immunodeficiency virus 1-positive subjects co-infected with herpes simplex virus 2.

Authors:  Brian R Long; Ann E Erickson; Joan M Chapman; Jason D Barbour; Bien-Aimee N Vu; Emily L Ho; Lewis L Lanier; Mariana M Sauer; Karina I Carvalho; Douglas F Nixon; Esper G Kallas
Journal:  Immunology       Date:  2009-08-04       Impact factor: 7.397

7.  SIV-induced Translocation of Bacterial Products in the Liver Mobilizes Myeloid Dendritic and Natural Killer Cells Associated With Liver Damage.

Authors:  Tristan I Evans; Haiying Li; Jamie L Schafer; Nichole R Klatt; Xing-Pei Hao; Ryan P Traslavina; Jacob D Estes; Jason M Brenchley; R Keith Reeves
Journal:  J Infect Dis       Date:  2015-08-03       Impact factor: 5.226

8.  Persistence of pathological distribution of NK cells in HIV-infected patients with prolonged use of HAART and a sustained immune response.

Authors:  Mario Frias; Antonio Rivero-Juarez; Ana Gordon; Angela Camacho; Sara Cantisan; Francisca Cuenca-Lopez; Julian Torre-Cisneros; Jose Peña; Antonio Rivero
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

9.  CD56negCD16⁺ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection.

Authors:  Jeffrey M Milush; Sandra López-Vergès; Vanessa A York; Steven G Deeks; Jeffrey N Martin; Frederick M Hecht; Lewis L Lanier; Douglas F Nixon
Journal:  Retrovirology       Date:  2013-12-18       Impact factor: 4.602

10.  Hypercytotoxicity and rapid loss of NKp44+ innate lymphoid cells during acute SIV infection.

Authors:  Haiying Li; Laura E Richert-Spuhler; Tristan I Evans; Jacqueline Gillis; Michelle Connole; Jacob D Estes; Brandon F Keele; Nichole R Klatt; R Keith Reeves
Journal:  PLoS Pathog       Date:  2014-12-11       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.